Due to their close contacts with patients, people working in the medical and nursing fields have a higher risk of infecting themselves and others with the COVID-19 coronavirus.
This World Pneumonia Day, Nov. 12, 2022, the Forum of International Respiratory Societies (FIRS), of which the American Thoracic Society is a founding member, is calling on governments and other stakeholders to take urgent action to tackle pneumonia - focusing on those who are at greatest risk of severe illness.
Following COVID-19 infection, there is significant new onset morbidity in children, adolescents and adults across 13 distinct diagnosis and symptom complexes, according to a new study.
Study suggests two-thirds of the global population may have antibodies from vaccination or infection.
A new study from Washington University School of Medicine in St. Louis and the Veterans Affairs St. Louis Health Care system shows the health consequences of COVID-19 reinfection. The researchers found that repeat SARS-CoV-2 infections contribute significant additional risk of adverse health conditions in multiple organ systems. Such outcomes include hospitalization; disorders affecting the lungs, heart, brain, and the body’s blood, musculoskeletal and gastrointestinal systems; and even death. Reinfection also contributes to diabetes, kidney disease and mental health issues.
Here are some of the latest articles that have been added to the Arthritis channel on Newswise.
Cases of respiratory illnesses – particularly RSV – are on the rise. A Penn State Health Children’s Hospital infectious disease physician explains why, and what you can do.
Pregnant people who received one of the mRNA COVID-19 vaccines had 10-fold higher antibody concentrations than those who were naturally infected with SARS-CoV-2, a finding that was also observed in their babies, according to a new study by researchers at Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania. The study, published today in JAMA Network Open, also found that vaccine timing played an important role in maximizing the transfer of antibodies, with antibodies detected as early as 15 days after the first vaccine dose and increasing for several weeks after.
Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that its phase 2 clinical trial of RSLV-132 in patients with long covid has been fully enrolled (NCT04944121).
Despite centuries of research, treating and curing cancer remains an urgent health research priority. With generous support from anonymous donors, the GastroIntestinal Research Foundation (GIRF) has launched a bold initiative, CA CURE, to identify and fund research to improve diagnostics and develop therapeutics focused on immunotherapies and personalized vaccines.
An early pandemic survey found that respondents’ intentions to receive COVID-19 vaccines were linked more to their media literacy and opinion of health experts than knowledge of the virus or previous vaccination behavior.
A new study conducted in England shows that the risk of death due to COVID-19 remains very low for children and young people, and most deaths occur in those with underlying health conditions. Marta Bertran of the UK Health Security Agency, London, and colleagues present these findings on November 8th in the open access journal PLOS Medicine.
New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, showed that a higher dose of pneumococcal vaccine safely and effectively improved antibody response in patients receiving rituximab for ANCA-associated vasculitis.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, showed that discontinuing methotrexate for 1 week after seasonal influenza vaccination provided the same seroprotection as a 2 week discontinuation period in patients with RA.
New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, demonstrated that withholding mycophenolate mofetil for 10 days significantly increased antibody response after 2 doses of COVID-19 vaccine, without a significant increase in flares.
New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found a greater number of preterm births in unvaccinated versus fully vaccinated pregnant patients with rheumatic disease and COVID-19.
Rutgers researchers find that one type of tissue-resident memory cell fights reinfection better than another.
Researchers comparing pre and post-pandemic surveys have found confidence in vaccinations is considerably lower post pandemic amongst all demographic groups.
Many more Utah teens are getting vaccinated for HPV, protecting them against six types of cancer. The state saw a significant increase in HPV vaccinations after a long history of mixed messages and misunderstandings about the vaccine. Huntsman Cancer Institute experts explain what’s working, and one woman tells about her harrowing cancer journey.
Monkeypox has infected more than 77,000 people in more than 100 countries worldwide, and — similar to COVID-19 — mutations have enabled the virus to grow stronger and smarter, evading antiviral drugs and vaccines in its mission to infect more people.
• In a population-level study of 1,105 adults with stable glomerular disease (a type of autoimmune kidney disease), a first dose of a COVID-19 vaccine was not associated with relapse risk; however, receiving a subsequent vaccine dose was associated with a 2-fold higher relative risk of relapse. • Importantly, the increase in absolute risk associated with vaccination was low (1–5% depending on type of glomerular disease), and most vaccine-associated disease flares were mild.
Researchers from the University of Missouri School of Medicine have discovered a high prevalence of COVID-19 co-infections in central Missouri during the 2021-2022 flu season, with a monthly co-infection rate as high as 48% among individuals with COVID-19.
Respiratory illnesses are affected the United States as winter approaches, and a "tridemic" is possible with the flu, COVID-19 and RSV.
A comprehensive review and meta-analysis of published research confirm that young adults (40 years old and younger) have a slightly elevated risk for myocarditis or pericarditis after mRNA COVID-19 vaccination.
One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found.
Free flu clinic. No registration needed.
COVID-19 vaccinations effectively reduce severe symptoms, hospitalizations, and death, which is why the Centers of Disease Control’s Advisory Committee on Immunization Practices will vote to add the COVID-19 vaccine to the recommended vaccine schedule for children.
Cancer immunotherapies, such as immune checkpoint inhibition therapy, have been attracting attention in recent years as new methods for treating cancer.
A Roundup of the Latest Medical Discoveries and Faculty News at Cedars-Sinai
A Rutgers expert provides guidance to those who might be at increased risk during pregnancy
Children aged 8 years or younger should be considered a group at high risk for more severe monkeypox disease, reports The Pediatric Infectious Disease Journal, the official journal of The European Society for Pediatric Infectious Diseases. The journal is published in the Lippincott portfolio by Wolters Kluwer.
Keeping your child safe and healthy is a multifaceted priority for families, starting with the ride home from the hospital in a properly installed car seat.
A Yale-designed nasal vaccine can help bolster immune responses to COVID-19 in previously vaccinated animals and reduce viral transmission, Yale researchers report Oct. 27 in the journal Science.
UC San Diego will be one of multiple sites assessing the safety and efficacy of tecovirimat as a potential treatment for human monkeypox. Marketed as TPOXX, tecovirimat is an antiviral currently approved for treatment of human smallpox in adults and children caused by the variola virus.
New research led by researchers at the University of Miami Miller School of Medicine and published in the Journal of Hepatology, suggests that getting a third dose of the COVID-19 mRNA vaccine could overcome the decreased vaccine respons in cirrhosis patients and offer strong protection against the virus, severe illness, and death from COVID-19.
The LJI team plans to use their new map of the Lassa virus surface glycoprotein to design a much-needed vaccine.
A new study from the Centers for Disease Control and Prevention’s VISION Network presents and analyzes some of the first real-world data on mRNA COVID vaccine effectiveness during Omicron BA.4 and BA.5 predominance for immunocompromised adults.
The Global Virus Network (GVN), representing 68 Centers of Excellence and 11 Affiliates in 39 countries comprising foremost experts in every class of virus causing disease in humans, and the Mahidol University in Thailand announced the addition of the Mahidol Virus Network as GVN’s newest Center of Excellence.
A subset of healthcare workers vaccinated against COVID-19 had unexpectedly low responses to the immunizations, according to Cedars-Sinai investigators. The findings of the new study are published in iScience, a Cell Press journal.
Cash transfers had limited outcomes for increasing vaccination efforts among adults, according to research led by Columbia University Mailman School of Public Health and the University of the Witwatersrand, Johannesburg (Wits).
Researchers at the University of Illinois College of Veterinary Medicine have demonstrated in a mouse model that a specific type of T cell, one of the body’s potent immune defenses, produces cytokines that are necessary for the body to acquire immunity against fungal pathogens.
Cedars-Sinai and other hospitals nationwide are seeing a surge in cases of pediatric RSV (respiratory syncytial virus) that are showing up earlier than expected this year. Healthcare providers are worried about the onset of the virus combined with the additional threats of the flu and COVID-19 as we head into winter.
Individuals who deal with anxiety are no less hesitant to get the COVID-19 vaccine compared to those without anxiety, according to new research.
New research on COVID-19 vaccine hesitancy in Black, Latinx communities could help shape more persuasive messages to boost uptake.
Preclinical studies in mice that model human COVID-19 suggest that an inexpensive, readily available amino acid might limit the effects of the disease and provide a new off-the-shelf therapeutic option for infections with SARS-CoV-2 variants and perhaps future novel coronaviruses.
A lecturer and his research team from Faculty of Veterinary Science, Chulalongkorn University, have developed “FLAVO INNOVAC” nanovaccine for the prevention of bacterial gills diseases in freshwater fish species such as Tilapia and freshwater Asian sea bass. This nanovaccine is an effective solution that reduces the risk of death from diseases and the limitations of vaccine injections.
The latest articles that have been added to the Environmental Health channel.
Among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery in this trial that enrolled more than 1,500 participants in the United States.
Drucilla J. Roberts, MD, from the Mass General Department of Pathology and colleagues recently published a literature review in the American Journal of Obstetrics & Gynecology, titled SARS-CoV-2 Placentitis, Stillbirth and Maternal COVID-19 Vaccination: Clinical-Pathological Correlations.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
